BRIEF published on 04/10/2025 at 19:05, 1 year 2 months ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 1 year 2 months ago Informations privilégiées / Autres communiqués TME Pharma augmente les ressources allouées au contrat de liquidité confié à Invest Securities pour renforcer la trésorerie. Détails des ressources disponibles après l'augmentation Contrat De Liquidité INVEST SECURITIES Trésorerie Ressources TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 1 year 2 months ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
BRIEF published on 02/17/2025 at 08:05, 1 year 4 months ago TME Pharma présente sa feuille de route stratégique et ses initiatives pour 2025 Biotechnologie Partenariats Stratégiques Thérapie Contre Le Cancer Découverte De Médicaments NOX-A12
BRIEF published on 02/17/2025 at 08:05, 1 year 4 months ago TME Pharma Outlines 2025 Strategic Roadmap and Initiatives Strategic Partnerships Biotechnology Drug Discovery Cancer Therapy NOX-A12
PRESS RELEASE published on 02/17/2025 at 08:00, 1 year 4 months ago Inside Information / Other news releases TME Pharma CEO Aram Mangasarian outlines key initiatives and milestones for 2025, including strategic partnerships, NOX-A12 clinical development, AI-driven drug discovery, and financial updates Strategic Partnerships Clinical Development CEO Message TME Pharma 2025 Initiatives
BRIEF published on 01/29/2025 at 08:05, 1 year 4 months ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
BRIEF published on 01/29/2025 at 08:05, 1 year 4 months ago TME Pharma et aimed analytics : Partenariat innovant pour la découverte de médicaments par l'IA Biotechnologie Partenariat Intelligence Artificielle Cancer Médicaments
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year 4 months ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year 4 months ago Informations privilégiées / Autres communiqués TME Pharma annonce une collaboration avec aimed analytics pour optimiser la découverte de médicaments par IA, renforçant son profil stratégique Collaboration IA Médicaments TME Pharma Aimed Analytics
Published on 06/27/2026 at 16:50, 9 hours 45 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 2 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 3 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 3 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 2 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 2 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 2 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 2 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 3 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
